Új utak a hajas sejtes leukémia és a rokon kórképek diagnosztikájában és kezelésében

Translated title of the contribution: Novelties in the diagnostics and therapy of hairy cell leukemia

Eszter Sári, Hajnalka Rajnai, Kitti Dénes, Csaba Bödör, Judit Csomor, Gábor Körösmezey, Ilona Tárkányi, Hanna Eid, Zsolt Nagy, J. Demeter

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Differential diagnosis of hairy cell leukemia (HCL) and related disorders (hairy cell leukemia variant and splenic marginal zone lymphoma) is of utmost importance since the treatment and prognosis of these lymphomas differ. Since 2011 diagnosis of hairy cell leukemia has been easier because of discovery of the disease defining somatic mutation BRAF V600E mutation, which has been also known as driver mutation in malignant melanoma. The presence of this mutation enabled targeted molecular therapy in HCL as well. As first line therapy purine nucleoside analogues are the gold standard, but refractory/relapsed patient are candidates for targeted BRAF-inhibitor therapy. This manuscript serves as guidance in making diagnosis and standard treatment of HCL, and summarizes newest data about molecular therapy, including our single center experience collected from 75 patients.

Original languageHungarian
Pages (from-to)137-144
Number of pages8
JournalMagyar Onkologia
Volume60
Issue number2
Publication statusPublished - Jun 6 2016

Fingerprint

Hairy Cell Leukemia
Mutation
Lymphoma
Molecular Targeted Therapy
Purine Nucleosides
Therapeutics
Melanoma
Differential Diagnosis

ASJC Scopus subject areas

  • Oncology

Cite this

Sári, E., Rajnai, H., Dénes, K., Bödör, C., Csomor, J., Körösmezey, G., ... Demeter, J. (2016). Új utak a hajas sejtes leukémia és a rokon kórképek diagnosztikájában és kezelésében. Magyar Onkologia, 60(2), 137-144.

Új utak a hajas sejtes leukémia és a rokon kórképek diagnosztikájában és kezelésében. / Sári, Eszter; Rajnai, Hajnalka; Dénes, Kitti; Bödör, Csaba; Csomor, Judit; Körösmezey, Gábor; Tárkányi, Ilona; Eid, Hanna; Nagy, Zsolt; Demeter, J.

In: Magyar Onkologia, Vol. 60, No. 2, 06.06.2016, p. 137-144.

Research output: Contribution to journalReview article

Sári, E, Rajnai, H, Dénes, K, Bödör, C, Csomor, J, Körösmezey, G, Tárkányi, I, Eid, H, Nagy, Z & Demeter, J 2016, 'Új utak a hajas sejtes leukémia és a rokon kórképek diagnosztikájában és kezelésében', Magyar Onkologia, vol. 60, no. 2, pp. 137-144.
Sári E, Rajnai H, Dénes K, Bödör C, Csomor J, Körösmezey G et al. Új utak a hajas sejtes leukémia és a rokon kórképek diagnosztikájában és kezelésében. Magyar Onkologia. 2016 Jun 6;60(2):137-144.
Sári, Eszter ; Rajnai, Hajnalka ; Dénes, Kitti ; Bödör, Csaba ; Csomor, Judit ; Körösmezey, Gábor ; Tárkányi, Ilona ; Eid, Hanna ; Nagy, Zsolt ; Demeter, J. / Új utak a hajas sejtes leukémia és a rokon kórképek diagnosztikájában és kezelésében. In: Magyar Onkologia. 2016 ; Vol. 60, No. 2. pp. 137-144.
@article{0b6cdd838b094edb91c13409f2bb13d2,
title = "{\'U}j utak a hajas sejtes leuk{\'e}mia {\'e}s a rokon k{\'o}rk{\'e}pek diagnosztik{\'a}j{\'a}ban {\'e}s kezel{\'e}s{\'e}ben",
abstract = "Differential diagnosis of hairy cell leukemia (HCL) and related disorders (hairy cell leukemia variant and splenic marginal zone lymphoma) is of utmost importance since the treatment and prognosis of these lymphomas differ. Since 2011 diagnosis of hairy cell leukemia has been easier because of discovery of the disease defining somatic mutation BRAF V600E mutation, which has been also known as driver mutation in malignant melanoma. The presence of this mutation enabled targeted molecular therapy in HCL as well. As first line therapy purine nucleoside analogues are the gold standard, but refractory/relapsed patient are candidates for targeted BRAF-inhibitor therapy. This manuscript serves as guidance in making diagnosis and standard treatment of HCL, and summarizes newest data about molecular therapy, including our single center experience collected from 75 patients.",
author = "Eszter S{\'a}ri and Hajnalka Rajnai and Kitti D{\'e}nes and Csaba B{\"o}d{\"o}r and Judit Csomor and G{\'a}bor K{\"o}r{\"o}smezey and Ilona T{\'a}rk{\'a}nyi and Hanna Eid and Zsolt Nagy and J. Demeter",
year = "2016",
month = "6",
day = "6",
language = "Hungarian",
volume = "60",
pages = "137--144",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - Új utak a hajas sejtes leukémia és a rokon kórképek diagnosztikájában és kezelésében

AU - Sári, Eszter

AU - Rajnai, Hajnalka

AU - Dénes, Kitti

AU - Bödör, Csaba

AU - Csomor, Judit

AU - Körösmezey, Gábor

AU - Tárkányi, Ilona

AU - Eid, Hanna

AU - Nagy, Zsolt

AU - Demeter, J.

PY - 2016/6/6

Y1 - 2016/6/6

N2 - Differential diagnosis of hairy cell leukemia (HCL) and related disorders (hairy cell leukemia variant and splenic marginal zone lymphoma) is of utmost importance since the treatment and prognosis of these lymphomas differ. Since 2011 diagnosis of hairy cell leukemia has been easier because of discovery of the disease defining somatic mutation BRAF V600E mutation, which has been also known as driver mutation in malignant melanoma. The presence of this mutation enabled targeted molecular therapy in HCL as well. As first line therapy purine nucleoside analogues are the gold standard, but refractory/relapsed patient are candidates for targeted BRAF-inhibitor therapy. This manuscript serves as guidance in making diagnosis and standard treatment of HCL, and summarizes newest data about molecular therapy, including our single center experience collected from 75 patients.

AB - Differential diagnosis of hairy cell leukemia (HCL) and related disorders (hairy cell leukemia variant and splenic marginal zone lymphoma) is of utmost importance since the treatment and prognosis of these lymphomas differ. Since 2011 diagnosis of hairy cell leukemia has been easier because of discovery of the disease defining somatic mutation BRAF V600E mutation, which has been also known as driver mutation in malignant melanoma. The presence of this mutation enabled targeted molecular therapy in HCL as well. As first line therapy purine nucleoside analogues are the gold standard, but refractory/relapsed patient are candidates for targeted BRAF-inhibitor therapy. This manuscript serves as guidance in making diagnosis and standard treatment of HCL, and summarizes newest data about molecular therapy, including our single center experience collected from 75 patients.

UR - http://www.scopus.com/inward/record.url?scp=84984913896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984913896&partnerID=8YFLogxK

M3 - Review article

VL - 60

SP - 137

EP - 144

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 2

ER -